4D-710 - 4D Molecular Therap
4D-710: "Single-dose administration of 4D-710 was well tolerated"; Cystic fibrosis (4D Molecular Therapeutics) - Jun 28, 2023 - ECFS 2023: "Clinically meaningful improvements in CFQ-R respiratory symptom score" 
P1/2 data • Cystic Fibrosis
https://4dmoleculartherapeutics.com/wp-content/uploads/ECFS-2023_Taylor-Cousar_4D-710_Final.pdf
 
Jun 28, 2023
 
 
99f57d23-b661-44b1-8cd8-3526969cb393.png

a3c3dca4-d129-45b2-bc60-256f8488dd34.png

d2cdfd6d-b2a3-46c9-84e2-cae6f9e3dadf.png